APO Research
Talk to an analyst

APO RESEARCH · REPORT

Psychiatric API

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Psychiatric API Market Outlook and Growth Opportunities 2026

22 December 2025202 pages

Choose your research edition.

Industry ResearchPsychiatric API Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Psychiatric API Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Psychiatric API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Psychiatric API Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Psychiatric API Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Psychiatric API market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Psychiatric API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Psychiatric API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Psychiatric API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Psychiatric API market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Psychiatric API market include Yaopharma, Yangtze River Pharmaceutical, Sichuan Chuanda West China Pharmaceutical, Ren An Pharmaceutical, Eli Lilly, Kanghong Pharmaceutical, Pfizer, Huahai Pharmaceutical and Hengrui Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Psychiatric API market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Psychiatric API and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Psychiatric API sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Psychiatric API market size, projected growth trends, production technologies, key applications, and end-use industries.

Psychiatric API Segment by Company

Yaopharma

Yangtze River Pharmaceutical

Sichuan Chuanda West China Pharmaceutical

Ren An Pharmaceutical

Eli Lilly

Kanghong Pharmaceutical

Pfizer

Huahai Pharmaceutical

Hengrui Pharmaceuticals

Herui Pharmaceutical

Dongting Pharmaceutical

Brilliant Pharmaceutical

Salutas Pharma

Germany Pharmaceutical

Dr.Reddy's Laboratories

Bora Pharmaceutical

Psychiatric API Segment by Type

Venlafaxine

Paroxetine

Duloxetine

Olanzapine

Others

Psychiatric API Segment by Application

Generalized Anxiety Disorder

Schizophrenia

Fibromyalgia

Major Depressive Disorder

Others

Psychiatric API Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Psychiatric API status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Psychiatric API market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Psychiatric API significant trends, drivers, influence factors in global and regions.

6. To analyze Psychiatric API competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psychiatric API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Psychiatric API and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psychiatric API.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Psychiatric API market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Psychiatric API industry.

Chapter 3: Detailed analysis of Psychiatric API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Psychiatric API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Psychiatric API in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Psychiatric API Industry Trends Table 2. Psychiatric API Industry Drivers Table 3. Psychiatric API Industry Opportunities and Challenges Table 4. Psychiatric API Industry Restraints Table 5. Global Psychiatric API Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Psychiatric API Revenue Share by Company (2021-2026) Table 7. Global Psychiatric API Sales Volume by Company (k units) & (2021-2026) Table 8. Global Psychiatric API Sales Volume Share by Company (2021-2026) Table 9. Global Psychiatric API Average Price (US$/unit) of Company (2021-2026) Table 10. Global Psychiatric API Company Ranking, (2024-2026) & (USD Million) Table 11. Global Psychiatric API Key Company Manufacturing Base & Headquarters Table 12. Global Psychiatric API Company, Product Type & Application Table 13. Global Psychiatric API Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Psychiatric API by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Venlafaxine Table 18. Significant Companies of Paroxetine Table 19. Significant Companies of Duloxetine Table 20. Significant Companies of Olanzapine Table 21. Significant Companies of Others Table 22. Global Psychiatric API Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Psychiatric API Sales Volume by Type (2021-2026) & (k units) Table 24. Global Psychiatric API Sales Volume by Type (2027-2032) & (k units) Table 25. Global Psychiatric API Sales Volume Share by Type (2021-2026) Table 26. Global Psychiatric API Sales Volume Share by Type (2027-2032) Table 27. Global Psychiatric API Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Psychiatric API Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Psychiatric API Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Psychiatric API Sales Value Share by Type (2021-2026) Table 31. Global Psychiatric API Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Generalized Anxiety Disorder Table 33. Significant Companies of Schizophrenia Table 34. Significant Companies of Fibromyalgia Table 35. Significant Companies of Major Depressive Disorder Table 36. Significant Companies of Others Table 37. Global Psychiatric API Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Psychiatric API Sales Volume by Application (2021-2026) & (k units) Table 39. Global Psychiatric API Sales Volume by Application (2027-2032) & (k units) Table 40. Global Psychiatric API Sales Volume Share by Application (2021-2026) Table 41. Global Psychiatric API Sales Volume Share by Application (2027-2032) Table 42. Global Psychiatric API Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Psychiatric API Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Psychiatric API Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Psychiatric API Sales Value Share by Application (2021-2026) Table 46. Global Psychiatric API Sales Value Share by Application (2027-2032) Table 47. Global Psychiatric API Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 48. Global Psychiatric API Sales by Region (2021-2026) & (k units) Table 49. Global Psychiatric API Sales Market Share by Region (2021-2026) Table 50. Global Psychiatric API Sales by Region (2027-2032) & (k units) Table 51. Global Psychiatric API Sales Market Share by Region (2027-2032) Table 52. Global Psychiatric API Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Psychiatric API Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Psychiatric API Sales Value Share by Region (2021-2026) Table 55. Global Psychiatric API Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Psychiatric API Sales Value Share by Region (2027-2032) Table 57. Global Psychiatric API Market Average Price (US$/unit) by Region (2021-2026) Table 58. Global Psychiatric API Market Average Price (US$/unit) by Region (2027-2032) Table 59. Global Psychiatric API Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 60. Global Psychiatric API Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Psychiatric API Sales by Country (2021-2026) & (k units) Table 62. Global Psychiatric API Sales Market Share by Country (2021-2026) Table 63. Global Psychiatric API Sales by Country (2027-2032) & (k units) Table 64. Global Psychiatric API Sales Market Share by Country (2027-2032) Table 65. Global Psychiatric API Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Psychiatric API Sales Value Market Share by Country (2021-2026) Table 67. Global Psychiatric API Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Psychiatric API Sales Value Market Share by Country (2027-2032) Table 69. Yaopharma Company Information Table 70. Yaopharma Business Overview Table 71. Yaopharma Psychiatric API Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Yaopharma Psychiatric API Product Portfolio Table 73. Yaopharma Recent Development Table 74. Yangtze River Pharmaceutical Company Information Table 75. Yangtze River Pharmaceutical Business Overview Table 76. Yangtze River Pharmaceutical Psychiatric API Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Yangtze River Pharmaceutical Psychiatric API Product Portfolio Table 78. Yangtze River Pharmaceutical Recent Development Table 79. Sichuan Chuanda West China Pharmaceutical Company Information Table 80. Sichuan Chuanda West China Pharmaceutical Business Overview Table 81. Sichuan Chuanda West China Pharmaceutical Psychiatric API Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Sichuan Chuanda West China Pharmaceutical Psychiatric API Product Portfolio Table 83. Sichuan Chuanda West China Pharmaceutical Recent Development Table 84. Ren An Pharmaceutical Company Information Table 85. Ren An Pharmaceutical Business Overview Table 86. Ren An Pharmaceutical Psychiatric API Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Ren An Pharmaceutical Psychiatric API Product Portfolio Table 88. Ren An Pharmaceutical Recent Development Table 89. Eli Lilly Company Information Table 90. Eli Lilly Business Overview Table 91. Eli Lilly Psychiatric API Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Eli Lilly Psychiatric API Product Portfolio Table 93. Eli Lilly Recent Development Table 94. Kanghong Pharmaceutical Company Information Table 95. Kanghong Pharmaceutical Business Overview Table 96. Kanghong Pharmaceutical Psychiatric API Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Kanghong Pharmaceutical Psychiatric API Product Portfolio Table 98. Kanghong Pharmaceutical Recent Development Table 99. Pfizer Company Information Table 100. Pfizer Business Overview Table 101. Pfizer Psychiatric API Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Pfizer Psychiatric API Product Portfolio Table 103. Pfizer Recent Development Table 104. Huahai Pharmaceutical Company Information Table 105. Huahai Pharmaceutical Business Overview Table 106. Huahai Pharmaceutical Psychiatric API Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Huahai Pharmaceutical Psychiatric API Product Portfolio Table 108. Huahai Pharmaceutical Recent Development Table 109. Hengrui Pharmaceuticals Company Information Table 110. Hengrui Pharmaceuticals Business Overview Table 111. Hengrui Pharmaceuticals Psychiatric API Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Hengrui Pharmaceuticals Psychiatric API Product Portfolio Table 113. Hengrui Pharmaceuticals Recent Development Table 114. Herui Pharmaceutical Company Information Table 115. Herui Pharmaceutical Business Overview Table 116. Herui Pharmaceutical Psychiatric API Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Herui Pharmaceutical Psychiatric API Product Portfolio Table 118. Herui Pharmaceutical Recent Development Table 119. Dongting Pharmaceutical Company Information Table 120. Dongting Pharmaceutical Business Overview Table 121. Dongting Pharmaceutical Psychiatric API Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Dongting Pharmaceutical Psychiatric API Product Portfolio Table 123. Dongting Pharmaceutical Recent Development Table 124. Brilliant Pharmaceutical Company Information Table 125. Brilliant Pharmaceutical Business Overview Table 126. Brilliant Pharmaceutical Psychiatric API Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Brilliant Pharmaceutical Psychiatric API Product Portfolio Table 128. Brilliant Pharmaceutical Recent Development Table 129. Salutas Pharma Company Information Table 130. Salutas Pharma Business Overview Table 131. Salutas Pharma Psychiatric API Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Salutas Pharma Psychiatric API Product Portfolio Table 133. Salutas Pharma Recent Development Table 134. Germany Pharmaceutical Company Information Table 135. Germany Pharmaceutical Business Overview Table 136. Germany Pharmaceutical Psychiatric API Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Germany Pharmaceutical Psychiatric API Product Portfolio Table 138. Germany Pharmaceutical Recent Development Table 139. Dr.Reddy's Laboratories Company Information Table 140. Dr.Reddy's Laboratories Business Overview Table 141. Dr.Reddy's Laboratories Psychiatric API Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. Dr.Reddy's Laboratories Psychiatric API Product Portfolio Table 143. Dr.Reddy's Laboratories Recent Development Table 144. Bora Pharmaceutical Company Information Table 145. Bora Pharmaceutical Business Overview Table 146. Bora Pharmaceutical Psychiatric API Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 147. Bora Pharmaceutical Psychiatric API Product Portfolio Table 148. Bora Pharmaceutical Recent Development Table 149. Key Raw Materials Table 150. Raw Materials Key Suppliers Table 151. Psychiatric API Distributors List Table 152. Psychiatric API Customers List Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources Table 156. Primary Sources List of Figures Figure 1. Psychiatric API Product Image Figure 2. Global Psychiatric API Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Psychiatric API Sales Value (2021-2032) & (US$ Million) Figure 4. Global Psychiatric API Sales (2021-2032) & (k units) Figure 5. Global Psychiatric API Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Psychiatric API Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Venlafaxine Image Figure 10. Paroxetine Image Figure 11. Duloxetine Image Figure 12. Olanzapine Image Figure 13. Others Image Figure 14. Global Psychiatric API Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Psychiatric API Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Psychiatric API Sales Volume Share by Type (2021-2032) Figure 17. Global Psychiatric API Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Psychiatric API Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Psychiatric API Sales Value Share by Type (2021-2032) Figure 20. Generalized Anxiety Disorder Image Figure 21. Schizophrenia Image Figure 22. Fibromyalgia Image Figure 23. Major Depressive Disorder Image Figure 24. Others Image Figure 25. Global Psychiatric API Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Psychiatric API Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Psychiatric API Sales Volume Share by Application (2021-2032) Figure 28. Global Psychiatric API Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Psychiatric API Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Psychiatric API Sales Value Share by Application (2021-2032) Figure 31. Global Psychiatric API Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 32. Global Psychiatric API Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Psychiatric API Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Psychiatric API Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Psychiatric API Sales Value (2021-2032) & (US$ Million) Figure 36. North America Psychiatric API Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Psychiatric API Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Psychiatric API Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Psychiatric API Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Psychiatric API Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Psychiatric API Sales Value (2021-2032) & (US$ Million) Figure 42. South America Psychiatric API Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Psychiatric API Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Psychiatric API Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Psychiatric API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Psychiatric API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Psychiatric API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Psychiatric API Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Psychiatric API Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Venlafaxine
  • Paroxetine
  • Duloxetine
  • Olanzapine
  • Others
Applications
  • Generalized Anxiety Disorder
  • Schizophrenia
  • Fibromyalgia
  • Major Depressive Disorder
  • Others
Companies covered
  • Yaopharma
  • Yangtze River Pharmaceutical
  • Sichuan Chuanda West China Pharmaceutical
  • Ren An Pharmaceutical
  • Eli Lilly
  • Kanghong Pharmaceutical
  • Pfizer
  • Huahai Pharmaceutical
  • Hengrui Pharmaceuticals
  • Herui Pharmaceutical
  • Dongting Pharmaceutical
  • Brilliant Pharmaceutical
  • Salutas Pharma
  • Germany Pharmaceutical
  • Dr.Reddy's Laboratories
  • Bora Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Psychiatric API Sales Value (2021-2032)
  4. 1.2.2 Global Psychiatric API Sales Volume (2021-2032)
  5. 1.2.3 Global Psychiatric API Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Psychiatric API Market Dynamics
  1. 2.1 Psychiatric API Industry Trends
  2. 2.2 Psychiatric API Industry Drivers
  3. 2.3 Psychiatric API Industry Opportunities and Challenges
  4. 2.4 Psychiatric API Industry Restraints
3 Psychiatric API Market by Company
  1. 3.1 Global Psychiatric API Company Revenue Ranking in 2025
  2. 3.2 Global Psychiatric API Revenue by Company (2021-2026)
  3. 3.3 Global Psychiatric API Sales Volume by Company (2021-2026)
  4. 3.4 Global Psychiatric API Average Price by Company (2021-2026)
  5. 3.5 Global Psychiatric API Company Ranking (2024-2026)
  6. 3.6 Global Psychiatric API Company Manufacturing Base and Headquarters
  7. 3.7 Global Psychiatric API Company Product Type and Application
  8. 3.8 Global Psychiatric API Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Psychiatric API Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Psychiatric API Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Psychiatric API Market by Type
  1. 4.1 Psychiatric API Type Introduction
  2. 4.1.1 Venlafaxine
  3. 4.1.2 Paroxetine
  4. 4.1.3 Duloxetine
  5. 4.1.4 Olanzapine
  6. 4.1.5 Others
  7. 4.2 Global Psychiatric API Sales Volume by Type
  8. 4.2.1 Global Psychiatric API Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Psychiatric API Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Psychiatric API Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Psychiatric API Sales Value by Type
  12. 4.3.1 Global Psychiatric API Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Psychiatric API Sales Value by Type (2021-2032)
  14. 4.3.3 Global Psychiatric API Sales Value Share by Type (2021-2032)
5 Psychiatric API Market by Application
  1. 5.1 Psychiatric API Application Introduction
  2. 5.1.1 Generalized Anxiety Disorder
  3. 5.1.2 Schizophrenia
  4. 5.1.3 Fibromyalgia
  5. 5.1.4 Major Depressive Disorder
  6. 5.1.5 Others
  7. 5.2 Global Psychiatric API Sales Volume by Application
  8. 5.2.1 Global Psychiatric API Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Psychiatric API Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Psychiatric API Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Psychiatric API Sales Value by Application
  12. 5.3.1 Global Psychiatric API Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Psychiatric API Sales Value by Application (2021-2032)
  14. 5.3.3 Global Psychiatric API Sales Value Share by Application (2021-2032)
6 Psychiatric API Regional Sales and Value Analysis
  1. 6.1 Global Psychiatric API Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Psychiatric API Sales by Region (2021-2032)
  3. 6.2.1 Global Psychiatric API Sales by Region: 2021-2026
  4. 6.2.2 Global Psychiatric API Sales by Region (2027-2032)
  5. 6.3 Global Psychiatric API Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Psychiatric API Sales Value by Region (2021-2032)
  7. 6.4.1 Global Psychiatric API Sales Value by Region: 2021-2026
  8. 6.4.2 Global Psychiatric API Sales Value by Region (2027-2032)
  9. 6.5 Global Psychiatric API Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Psychiatric API Sales Value (2021-2032)
  12. 6.6.2 North America Psychiatric API Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Psychiatric API Sales Value (2021-2032)
  15. 6.7.2 Europe Psychiatric API Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Psychiatric API Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Psychiatric API Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Psychiatric API Sales Value (2021-2032)
  21. 6.9.2 South America Psychiatric API Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Psychiatric API Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Psychiatric API Sales Value Share by Country, 2025 VS 2032
7 Psychiatric API Country-level Sales and Value Analysis
  1. 7.1 Global Psychiatric API Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Psychiatric API Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Psychiatric API Sales by Country (2021-2032)
  4. 7.3.1 Global Psychiatric API Sales by Country (2021-2026)
  5. 7.3.2 Global Psychiatric API Sales by Country (2027-2032)
  6. 7.4 Global Psychiatric API Sales Value by Country (2021-2032)
  7. 7.4.1 Global Psychiatric API Sales Value by Country (2021-2026)
  8. 7.4.2 Global Psychiatric API Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Psychiatric API Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Psychiatric API Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Psychiatric API Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Psychiatric API Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Psychiatric API Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Psychiatric API Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Psychiatric API Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Psychiatric API Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Psychiatric API Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Psychiatric API Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Psychiatric API Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Psychiatric API Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Psychiatric API Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Psychiatric API Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Psychiatric API Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Psychiatric API Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Psychiatric API Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Psychiatric API Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Psychiatric API Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Psychiatric API Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Psychiatric API Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Psychiatric API Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Psychiatric API Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Psychiatric API Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Psychiatric API Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Psychiatric API Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Psychiatric API Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Psychiatric API Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Psychiatric API Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Psychiatric API Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Psychiatric API Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Psychiatric API Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Psychiatric API Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Psychiatric API Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Psychiatric API Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Psychiatric API Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Psychiatric API Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Psychiatric API Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Psychiatric API Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Psychiatric API Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Psychiatric API Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Psychiatric API Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Psychiatric API Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Psychiatric API Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Psychiatric API Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Psychiatric API Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Psychiatric API Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Psychiatric API Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Psychiatric API Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Psychiatric API Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Psychiatric API Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Psychiatric API Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Psychiatric API Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Psychiatric API Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Psychiatric API Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Psychiatric API Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Psychiatric API Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Psychiatric API Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Psychiatric API Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Psychiatric API Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Psychiatric API Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Psychiatric API Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Psychiatric API Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Psychiatric API Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Psychiatric API Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Psychiatric API Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Psychiatric API Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Psychiatric API Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Psychiatric API Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Psychiatric API Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Psychiatric API Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Psychiatric API Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Psychiatric API Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Psychiatric API Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Psychiatric API Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Psychiatric API Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Psychiatric API Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Psychiatric API Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Psychiatric API Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Psychiatric API Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Psychiatric API Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Psychiatric API Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Psychiatric API Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Psychiatric API Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Yaopharma
  2. 8.1.1 Yaopharma Company Information
  3. 8.1.2 Yaopharma Business Overview
  4. 8.1.3 Yaopharma Psychiatric API Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Yaopharma Psychiatric API Product Portfolio
  6. 8.1.5 Yaopharma Recent Developments
  7. 8.2 Yangtze River Pharmaceutical
  8. 8.2.1 Yangtze River Pharmaceutical Company Information
  9. 8.2.2 Yangtze River Pharmaceutical Business Overview
  10. 8.2.3 Yangtze River Pharmaceutical Psychiatric API Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Yangtze River Pharmaceutical Psychiatric API Product Portfolio
  12. 8.2.5 Yangtze River Pharmaceutical Recent Developments
  13. 8.3 Sichuan Chuanda West China Pharmaceutical
  14. 8.3.1 Sichuan Chuanda West China Pharmaceutical Company Information
  15. 8.3.2 Sichuan Chuanda West China Pharmaceutical Business Overview
  16. 8.3.3 Sichuan Chuanda West China Pharmaceutical Psychiatric API Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sichuan Chuanda West China Pharmaceutical Psychiatric API Product Portfolio
  18. 8.3.5 Sichuan Chuanda West China Pharmaceutical Recent Developments
  19. 8.4 Ren An Pharmaceutical
  20. 8.4.1 Ren An Pharmaceutical Company Information
  21. 8.4.2 Ren An Pharmaceutical Business Overview
  22. 8.4.3 Ren An Pharmaceutical Psychiatric API Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Ren An Pharmaceutical Psychiatric API Product Portfolio
  24. 8.4.5 Ren An Pharmaceutical Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Psychiatric API Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Psychiatric API Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Kanghong Pharmaceutical
  32. 8.6.1 Kanghong Pharmaceutical Company Information
  33. 8.6.2 Kanghong Pharmaceutical Business Overview
  34. 8.6.3 Kanghong Pharmaceutical Psychiatric API Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Kanghong Pharmaceutical Psychiatric API Product Portfolio
  36. 8.6.5 Kanghong Pharmaceutical Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Psychiatric API Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Psychiatric API Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Huahai Pharmaceutical
  44. 8.8.1 Huahai Pharmaceutical Company Information
  45. 8.8.2 Huahai Pharmaceutical Business Overview
  46. 8.8.3 Huahai Pharmaceutical Psychiatric API Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Huahai Pharmaceutical Psychiatric API Product Portfolio
  48. 8.8.5 Huahai Pharmaceutical Recent Developments
  49. 8.9 Hengrui Pharmaceuticals
  50. 8.9.1 Hengrui Pharmaceuticals Company Information
  51. 8.9.2 Hengrui Pharmaceuticals Business Overview
  52. 8.9.3 Hengrui Pharmaceuticals Psychiatric API Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Hengrui Pharmaceuticals Psychiatric API Product Portfolio
  54. 8.9.5 Hengrui Pharmaceuticals Recent Developments
  55. 8.10 Herui Pharmaceutical
  56. 8.10.1 Herui Pharmaceutical Company Information
  57. 8.10.2 Herui Pharmaceutical Business Overview
  58. 8.10.3 Herui Pharmaceutical Psychiatric API Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Herui Pharmaceutical Psychiatric API Product Portfolio
  60. 8.10.5 Herui Pharmaceutical Recent Developments
  61. 8.11 Dongting Pharmaceutical
  62. 8.11.1 Dongting Pharmaceutical Company Information
  63. 8.11.2 Dongting Pharmaceutical Business Overview
  64. 8.11.3 Dongting Pharmaceutical Psychiatric API Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Dongting Pharmaceutical Psychiatric API Product Portfolio
  66. 8.11.5 Dongting Pharmaceutical Recent Developments
  67. 8.12 Brilliant Pharmaceutical
  68. 8.12.1 Brilliant Pharmaceutical Company Information
  69. 8.12.2 Brilliant Pharmaceutical Business Overview
  70. 8.12.3 Brilliant Pharmaceutical Psychiatric API Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Brilliant Pharmaceutical Psychiatric API Product Portfolio
  72. 8.12.5 Brilliant Pharmaceutical Recent Developments
  73. 8.13 Salutas Pharma
  74. 8.13.1 Salutas Pharma Company Information
  75. 8.13.2 Salutas Pharma Business Overview
  76. 8.13.3 Salutas Pharma Psychiatric API Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Salutas Pharma Psychiatric API Product Portfolio
  78. 8.13.5 Salutas Pharma Recent Developments
  79. 8.14 Germany Pharmaceutical
  80. 8.14.1 Germany Pharmaceutical Company Information
  81. 8.14.2 Germany Pharmaceutical Business Overview
  82. 8.14.3 Germany Pharmaceutical Psychiatric API Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Germany Pharmaceutical Psychiatric API Product Portfolio
  84. 8.14.5 Germany Pharmaceutical Recent Developments
  85. 8.15 Dr.Reddy's Laboratories
  86. 8.15.1 Dr.Reddy's Laboratories Company Information
  87. 8.15.2 Dr.Reddy's Laboratories Business Overview
  88. 8.15.3 Dr.Reddy's Laboratories Psychiatric API Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Dr.Reddy's Laboratories Psychiatric API Product Portfolio
  90. 8.15.5 Dr.Reddy's Laboratories Recent Developments
  91. 8.16 Bora Pharmaceutical
  92. 8.16.1 Bora Pharmaceutical Company Information
  93. 8.16.2 Bora Pharmaceutical Business Overview
  94. 8.16.3 Bora Pharmaceutical Psychiatric API Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Bora Pharmaceutical Psychiatric API Product Portfolio
  96. 8.16.5 Bora Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Psychiatric API Value Chain Analysis
  2. 9.1.1 Psychiatric API Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Psychiatric API Sales Mode & Process
  6. 9.2 Psychiatric API Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Psychiatric API Distributors
  9. 9.2.3 Psychiatric API Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst